Free tool
FAERS Monitor: Lokelma
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207078 or its brand name (Lokelma, Sodium Zirconium Cyclosilicate). Reports on generic versions are filed under their own applications.
Reports
4,008
Serious
3,277
82% of reports
Hospitalization
1,089
Death reported
1,441
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,159
- blood potassium increased206
- hyperkalaemia186
- diarrhoea180
- constipation127
- off label use127
- cardiac failure95
- nausea94
- renal failure94
- vomiting89
- acute kidney injury84
- pneumonia80
- chronic kidney disease79
- renal impairment78
- drug ineffective77
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 10 |
| 2019 | 112 |
| 2020 | 200 |
| 2021 | 262 |
| 2022 | 387 |
| 2023 | 541 |
| 2024 | 828 |
| 2025 | 863 |
| 2026 | 805 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood potassium increasedSignal | 206 | 67.5 | 59.0 | 13,260 |
| hyperkalaemiaSignal | 186 | 28.0 | 24.3 | 4,795 |
| deathSignal | 1,159 | 7.1 | 6.7 | 6,281 |
| cardiac failureSignal | 95 | 6.2 | 5.1 | 412 |
| chronic kidney diseaseSignal | 79 | 5.5 | 4.4 | 284 |
| renal impairmentSignal | 78 | 4.9 | 3.9 | 237 |
| renal failureSignal | 94 | 3.7 | 3.0 | 185 |
| constipationSignal | 127 | 3.1 | 2.6 | 175 |
| acute kidney injurySignal | 84 | 2.9 | 2.3 | 102 |
| diarrhoea | 180 | 1.5 | 1.3 | 27 |
| pneumonia | 80 | 1.3 | 1.0 | 5 |
| vomiting | 89 | 1.0 | 0.8 | 0 |
| off label use | 127 | 0.8 | 0.6 | 10 |
| nausea | 94 | 0.6 | 0.5 | 22 |
| drug ineffective | 77 | 0.3 | 0.2 | 128 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.